Abstract: Chaperone therapy is a newly developed molecular approach to lysosomal diseases, a group of human genetic diseases causing severe brain damage. We found two valienamine derivatives, and N-octyl-β-valienamine (NOV), as promising therapeutic agents for human β-galactosidase defi ciency disorders (mainly G M1 -gangliosidosis) and β-glucosidase defi ciency disorders (Gaucher disease), respectively. We briefl y reviewed the historical background of research in carbasugar glycosidase inhibitors. Originally NOEV and NOV had been discovered as competitive inhibitors, and then their paradoxical bioactivities as chaperones were confi rmed in cultured fi broblasts from patients with these disorders. Subsequently G M1 -gangliosidosis model mice were developed and useful for experimental studies. Orally administered NOEV entered the brain through the blood-brain barrier, enhanced β-galactosidase activity, reduced substrate storage, and improved neurological deterioration clinically. Furthermore, we executed computational analysis for prediction of molecular interactions between β-galactosidase and NOEV. Some preliminary results of computational analysis of molecular interaction mechanism are presented in this article. NOV also showed the chaperone effect toward several β-glucosidase gene mutations in Gaucher disease. We hope chaperone therapy will become available for some patients with G M1 -gangliosidosis, Gaucher disease, and potentially other lysosomal storage diseases with central nervous system involvement.
Introduction
Lysosome is one of the cellular organelles where various high molecular endogenous or exogenous compounds are systematically digested under the acidic condition. 1 This physiological catalytic process is disturbed if mutations occur in one of the genes coding for the hydrolytic enzymes in the lysosome. Celllular dysfunctioin caused by an excessive storage of substrates ensues, and a genetic metabolic disease (lysosomal disease) develops clinically in humans and other animals with neurological and other somatic manifestations. This concept was fi rst proposed for glycogen storage disease type I. 2 Since the mid-1960s, attempts have been made to the development of therapy for patients with lysosomal diseases. Theorectically enzyme replacement therapy was the most promising approach, and eventually shown to be effective for Gaucher disease patients, the most prevalent metabolic storage disorder of humans. 3 This approach has been extended to other lysosomal diseases. However, the effect has not been confi rmed to brain pathology in patients with neurological manifestations.
G M1 -gagliosidosis is one of the lysosomal diseases with storage of ganglioside G M1 , keratan sulfate, and glycoprotein-derived oligosaccharides, presenting clinically with progressive neurological deterioration mainly in infancy and childhood. 4 This disease has been our major target of research for more than 40 years. We analyzed correlation of phenotypic manifestations with storage compounds, 5 enzyme activities, 6, 7 and enzyme molecules. 8, 9 Finally we moved to molecular pathology of β-galactosidase.
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In parallel with with these experiments, in the early 1990s, we started molecular analyses of two genetically distinct human disease groups, β-galactosidosis (β-galactosidase defi ciency disorders) caused by β-galactosidase gene mutations 4 and Fabry disease caused by α-galactosidase A gene mutations.
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A paradoxical phenomenon was found that galactose itself and anologous low molecular weight competitive inhibitors could serve as chemical chaperones to induce expression of catalytic activities of mutant enzymes after stabilization and successful intracellular transport to the lysosome in the cells. We reported this enhancement fi rst in Fabry disease, 12, 13 and then in G M1 -gangliosidosis 14 and Gaucher disease. 15 After our early studies on galactose and 1-deoxygalactonojirimycin (DGJ), we developed new valienamine derivatives, N-octyl-4-epi-β-valienamine (NOEV) and N-octyl-β-valienamine (NOV) as chemical chaperones for mutant β-galactosidase and β-glucosidase proteins, respectively, to restore the enzyme activity in somatic cells from patients with G M1 -gangliosidosis and Gaucher disease. [14] [15] [16] We hope that this phenomenon will be applied to development of novel molecular therapeutic approach to lysosomal diseases, particularly with severe brain damage, in the near future. In this article we summarize our experimental results of chaperone effect and chaperone therapy mainly on NOEV for G M1 -gangliosidosis.
Competitive Inhibitors of Lysosomal Enzymes
Carbasugar glycosidase inhibitors and related bioactive compounds Carbasugars, previously known as pseudosugars, are a family of sugar mimics currently attracting interest among researchers in glycobiology and chemistry fi elds. [17] [18] [19] The fi rst example of carba-α-talopyranose was synthesized and called "pseudosugars." 20 Later, naturally occurring bioactive carbasugar, 5a-carba-α-D-galactopyranose, was discovered. 21 Carbasugars are (hydroxymethyl)-branched-chain cyclitols. They are topologically similar to normal sugars particularly in the arrangement of the hydroxyl and hydroxymethyl groups, but have the oxygen atom of the pyranose or furanose ring replaced by methylene. Humans cannot differentiate carbaglucose from true glucose by their taste. 22 Furthermore carbahexopyranoses exist in structurally stable α-and β-anomer forms which are not interconvertible. Therefore, chemical modifi cation at C-1 positions may be possible, providing biologically interesting compounds. Potent glycosidase inhibitors NOEV 1 and NOV 2 (Fig. 1A) are synthetic 5,5a-unsaturated 5a-carba-β-galacto and glucopyranosylamine derivatives, respectively.
In 1970, agrochemical antibiotic validamycin A 3 and homologues were discovered 23 and have so far been utilized to control sheath bright disease of rice plant (Fig. 1B) . During their structural elucidation, three components were isolated: valienamine 5, validamine 6, 24 and valiolamine 7.
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These compounds are strong α-glucosidase inhibitors themselves. In 1976, α-amylase inhibitor acarbose 4 composed of 5 was discovered 26 and has been clinically used to control diabetes.
Structural modifi cation of valienamine
The enzyme inhibitory potency of 4 has been attributed to the core structure of methyl acarviosin 10, a strong α-glucosidase inhibitor, and considered to be an analogue of transition-state structure postulated for enzymatic hydrolysis of maltose 27 ( Fig. 1C) . The potency of 3 has been attributed to strong trehalase inhibition in vitro by validoxylamine A 9 that mimicks the transition-state structure for hydrolysis of trehalose with trehalase. The valienamine moiety of 9 and 10 holds the pyranoid oxonium ion structures and binds more fi rmly to the corresponding active sites of enzymes via an imminium ion. Thus, they are competitive inhibitors, explaining a structural correlation between inhibitors and substrates. This knowledge opened up the possibility for development of therapeutically useful carbasugar derivatives. Thus, chemical modifi cation of three components 5-7 was stimulated by successful medical application of 4 (Fig. 1B) , leading to a fi nding of semisynthetic voglibose 8, N- (1,3-dihydroxyprop-2-yl) valiolamine that is fully compatible to 4. 28, 29 One of the authors (SO) became interested in chemical modifi cation of 5 and 6, and designed some stereoisomers by analogy of the structural relationship between enzyme inhibitors and substrates. However, both the C-1 epimers of 5 and 6 unexpectedly lacked activity against β-glucosidase. Then valienamine-type glycosidase inhibitors 11-13 with β-gluco, α-manno, and β-galacto confi gurations, expected to be specifi c inhibitors of the corresponding hydrolases, were synthesized 30, 31 (Fig. 1D) . However, notable inhibitory activity could not be observed for any of them. Bioassay of the activity was carried out routinely using commercially available glycosidases. Although simple chemical modifi cation of these amines, such as N-alkylation, might have improved their potency, the activity of intact amines should be a reliable hallmark for further development of its related compounds. Undoubtedly, biochemical features of 5 and 6 have been important models for further successful development.
Glycocerebrosidase inhibitors: carbaglycosylceramides
Some glycosylamides are signifi cant immunomodulators. 32 We prepared some carbasugar analogues, such as compound 14, as bioactive glycosylamides 33 ( Fig. 1E ). This result suggested that the carbohydrate moiety of glycolipids could possibly be replaced to give rise to biologically active carbohydrate mimics.
Then a carbasugar mimic 15 of glucosylceramide was found to be a moderate inhibitor of glucocerebrosidase. 34 Further attempts were made to prepare valienamine analogues 16 and 17, carbaglucosyl and carbagalactosylceramides, 35 which exhibited potent and specifi c inhibitory activity against the corresponding gluco-(IC 50 , 0.3 μM; bovine liver) and galacto-cerebrosidases (IC 50 , 2.7 μM; bovine liver).
N-Alkyl valienamines, potent β-galactosidase inhibitors
Complex ceramide chains were synthetically inaccessible. We therefore began to modify the structure by introducing a simple substitution of ceramide chain. Replacement with a simple aliphatic chain resulted in an increase of inhibitory activity 36 ( Fig. 1D) . Table 1 shows enzyme inhibitory activity of N-alkyl derivatives 1, 2, 11a-d, and 13a-c [R=(CH 2 ) n CH 3 ]toward some glycosidases. 19, 37 N-Octyl derivatives 1 and 2 were most promising for medical application. 38 Biochemical role of N-octyl portion was predicted also by computer-assisted simulation studies (Sakakibara, unpublished data).
Preparative studies on valienamine type inhibitors
For further development of carbasugar chemistry, simple synthetic precursors are required. DielsAlder endo-adduct 18(+), (-) of furan and acrylic acid has been useful for this purpose. Preparative intermediates reported in previous studies 19 could also be provided as optically pure forms from common hexopyranoses 39 providing a convenient link of carba to true sugars. Optical resolution of racemic 18 could be readily conducted through fractional crystallization of the diastereomeric salt with optically active α-phenylethylamines, 40 or enantioselective hydrolysis of the racemic 2-chloroethyl epoxy esters by means of pig liver esterase (Sugai et al. unpublished data).
Typical routes to valienamines related to NOEV 1 and NOV 2 were briefly described 41 ( Fig. 2A ). Optically resolved endo-adduct 18(-) with L-stereochemistry was converted into 1,6-dibromo-1,6-dideoxy-β-carbaglucose 20 through the triol 19. Elimination of 20 with 1,8-diazabicyclo [5.4 .0]undec-7-ene (DBU) gave the conjugate alkadiene 21, which was transformed into 1,4-dibromides 22α,β. The primary bromo group was fi rst replaced with an acetate ion and then the secondary one with azide anion to give α,β-mixture of the azide precursors 23α,β. The azido function was reduced with H 2 S or Ph 3 P to give the free bases 5 and 11.
Effective N-alkylation of 11 is important for provision of active compounds. Compound 23β was protected and reduced (→24). The free amine 24 was treated with a series of acid chlorides to give the amides (25) . Reduction of 25 with lithium aluminum hydride (LAH) (→26), followed by deprotection, afforded the N-alkyl valienamines (→NOV 2, 11a-d) in good yields. 36 NOEV 1 is the 4-epimer of 2. Preparation of 1 was fi rst conducted cumbersomely by Walden inversion at C-4 of 2 through oxidation of 4-OH, followed by selective reduction. 38 Alternatively, 18(+) was converted into the bromo acetate (27) , which was cleaved with HBr to give the tribromide (28) (Fig. 2B ). Compound 28 was treated with methoxide and the resulting anhydride was opened and then acetylated to give the dibromide (29) . Dehydrobromination (→30) followed by protection gave the alkadiene 31. Treatment with bromine gave the 1,4-dibromide (32), which was similarly converted into the bromide 33. Thus 33 was similarly transformed into the β-valienamine 13 with β-galacto configuration. Modification of the β-galactose-type valienamine will be achieved by direct displacement of bromide 33 with alkyl amine (→34). The substitution reaction selectively occurs as expected by neighboring assistance of the 2-acetoxyl or through direct S N 2 fashion to afford, after deprotection, N-alkyl-4-epi-β-valienamines (13a-c) including NOEV. inaccessibility to the carbahexose skeletons. Recently, we identifi ed some routes to carbasugars through chemical transformation of (-)-vibo-quercitol derived from myo-inositol by biogenesis (Fig. 2C) . 42, 43 This route establishes a link between naturally abundant cyclitols and chiral carbasugars.
Future aspect
Carbaglycosylamines are chemically stable (hydroxymethyl) aminocylitols and expected to play roles as non-hydrolyzable mimics of glycopyranosylamines. 43, 44 Diverse modifi cation of the biochemical and topologic nature of carbaglycosylamines may be achieved by substitution at the anomeric position, unsaturation at C-5 and C-5a, and hydroxylation at C-5 and/or C-5a, leading to improvement of biological function. As shown by the inhibitory activity of the N-alkyl derivatives 11a-d and 13a-c of β-valienamines, the inclusion of hydrophobic N-alkyl chains is likely to contribute to improvement of its potential significance. Furthermore, additional modifi cation of their physicochemical nature is advisable for the purpose of generating strong binding to active sites of enzyme or peptide molecules.
β-Galactosidosis: Genetic Human Disorders Caused by β-Galactosidase Gene Mutations
Lysosomal β-galactosidase (EC 3.2. 46 More than 100 gene mutations are collected, and successful gene diagnosis is well established using restriction enzymes specifi c to individual mutations. 4 At present only symptomatic therapy is available for the brain lesion in human G M1 -gangliosidosis patients. Enzyme replacement therapy is currently in use for clinical practice for Gaucher disease, Fabry disease and other lysosomal diseases. However, the benefi cial effect has not been confirmed for the brain damage, although general somatic signs and symptoms are clearly improved by continuous enzyme replacement therapy. 47 Secretion of feline β-galactosidase was reported in the transfected cell culture system, but the effect on the central nervous system was not shown. 48 After several years of basic investigations mainly for mutant α-galactosidase A in Fabry disease, we proposed chemical chaperone therapy for brain pathology in G M1 -gangliosidosis, using an in vitro enzyme inhibitor N-octyl-4-epi-β-valienamine (NOEV) (1; Fig. 1A ), a chemical compound newly produced by organic synthesis described above, 38 as a potent stabilizer of mutant β-galactosidase in somatic cells from patients with this disorder. We tested these possibilities fi rst in Fabry disease, and found some mutant enzyme proteins were unstable at neutral pH in the endoplasmic reticulum/ Golgi apparatus, and rapidly degraded because of inappropriate molecular folding. 50 Addition of galactose in the culture medium of lymphoblasts from Fabry patients and COS-1 cells expressing mutant enzyme proteins surprisingly induced a high expression of α-galactosidase A activity. 12 However, a high concentration of galactose was necessary for treatment of these enzyme-defi cient cells in culture. We concluded that a long-term treatment with galactose at this high dose was not realistic, although a short-term human experiment was reported on the beneficial cardiac function in a case of Fabry disease. 51 Accordingly we searched for other compounds that could enhance the enzyme activity in mutant cells. As stated above, DGJ was found to be effective for stabilization and high expression of the enzyme activity. 13, 52 DGJ showed the chaperone effect mainly on mutant α-galactosidae A. Its activity toward mutant β-galactosidase was 50-fold lower in a culture system experiment. 53 After subsequent extensive molecular analysis we reached the following conclusion. 49 A substrate analogue inhibitor binds to the misfolded mutant lysosomal protein as a kind of molecular chaperone (chemical chaperone), to achieve normal molecular folding at the endoplasmic reticulum/Golgi compartment in somatic cells, resulting in formation of a stable molecular complex at neutral pH. The protein-chaperone complex is safely transported to the lysosome, where it dissociates under the acidic conditions, the mutant enzyme remains stabilized in its normal folding, and its catalytic function is expressed (see below; Fig. 4 ).
Therapeutic Approach to Brain Pathology by Chemical Chaperones New chaperones: valienamine derivatives
We had particular interest in primary neuronopathic lysosomal diseases. Accordingly after studies on galactose and DGJ for α-galactosidase A, we started an extensive search for specifi c compounds for β-galactosidase. No commercially available compound was found as bioactive chaperone. Fortunately we came across two synthetic valienamine derivatives: β-galactosidase inhibitor N-octyl-4-epi-β-valienamine (NOEV) and β-glucosidase inhibitor N-octyl-β-valienamine (NOV) (1 and 2; Fig. 1A) . NOV was the fi rst compound synthesized as a glucocerebrosidase inhibitor, 36 and subsequently NOEV was synthesized by epimerization of NOV. 37 They are specifi c competitive inhibitors of β-galactosidase and β-glucosidase, respectively, In our laboratory NOEV studies moved faster than NOV simply because of accumulation of more experimental data and clinical materials for β-galactosidase and G M1 -gangliosidosis.
NOEV is a potent inhibitor of lysosomal β-galactosidase in vitro. It is stable and soluble in methanol or DMSO. The hydrochloride salt is freely soluble in water. Molecular weight is 287.40. IC 50 is 0.125 μM toward human β-galactosidase.
14 NOEV is 50-fold more active than DGJ in chaperone effect on mutant human β-galactosidase in G M1 -gangliosidosis. Our calculations suggest that at least 10% of normal enzyme activity is necessary for washout of the storage substrate in lysosomal diseases (Fig. 3) . The age of onset in Figure 3 . Correlation between residual β-galactosidase activity and clinical onset. The amount of residual enzyme activity shows positive parabolic correlation with the age of onset in various phenotypic forms of β-galactosidase deficiency disorders. The enzyme activity is generally less than 3% of the control mean in infantile G M1 -gangliosidosis, 3%-6% in juvenile G M1 -gangliosidosis, and more than 6% in late onset (adult/chronic) G M1 -gangliosidosis and Morquio B disease. At least 10% of normal enzyme activity is necessary for washout of the storage substrate. The age of onset in patients expressing enzyme activity above this level is theoretically beyond the human life span. This fi gure is based on the enzyme assay results using cultured skin fibroblasts and a synthetic fl uorogenic substrate 4-methylumbelliferyl β-galactopyranoside. In this calculation, for technical reasons, substrate specifi city is not taken into account, although mutant enzymes show different spectrum in G M1 -gangliosidosis and Morquio B disease.
patients expressing enzyme activity above this level is theoretically beyond the human life span. The same calculation was reported on some other lysosomal diseases. 54 We anticipate that the effective NOEV concentrations in human cells and animal tissues are much lower than the IC 50 calculated in vitro, based on the results of tissue concentration after oral NOEV administration in experimental model mice. 55 In fact, NOEV is effective at the IC 50 concentration in the culture medium for enhancement of mutant enzyme activity. 16 We hope it will be clinically used as a specifi c enzyme enhancer without exerting inhibitory effect in the cells.
Chaperone experiments on culture cells
About one-third of the cultured fi broblast strains from G M1 -gangliosidosis patients responded to NOEV; mainly from juvenile form and some infantile form patients. The effect is mutationspecifi c. 16 The R457Q mutant responded to NOEV maximally at 0.2 μM, and the R201C or R201H mutant at 2 μM. The mouse fi broblasts expressing mutant human β-galactosidase showed essentially the same results. 53 Molecular interaction between the chaperone and mutant protein depends on the structural modifi cation of the mutant enzyme protein (Sakakibara et al. unpublished data). Addition of ganglioside mixture in the culture medium increased intracellular G M1 in the R201C cells causing juvenile G M1 -gangliosidosis. 14 This storage was almost completely prevented by NOEV.
Chaperone experiments on genetically engineered G M1 -gangliosidosis model mice
For animal studies we developed a knockout (KO) mouse strain with complete defi ciency of β-galactosidase, 56 and then a transgenic (Tg) strain based on KO, expressing human R201C mutation (4% of the enzyme activity in the brain from wild-type mice).
14 Both showed neurological deterioration with some difference in severity. Life span was 7-10 months for KO and 12-18 months for Tg. Neuropathology corresponded to the clinical severity. 14 Short-term oral NOEV administration resulted in signifi cant enhancement of the enzyme activity in all the R201C mouse tissues examined, including the brain.
14 Immunohistochemstry revealed an increase in β-galactosidase activity and decrease in G M1 and G A1 storage.
Oral NOEV treatment for the R201C Tg mouse showed an increase of the NOEV content in the brain in parallel with β-galactosidase activity, and G M1 storage decreased. 55 NOEV disappeared rapidly, within a few days after withdrawal. In this study we tried a new scoring system for neurological assessment 57 ( Table 2 ). Treatment at the very early clinical stage (2 months) resulted in a positive clinical effect within a few months, although complete arrest or prevention of disease progression was not achieved under this experimental condition (Table 3 ). The latency before the clinical effect was longer if the therapy was started in the late symptomatic stage (6 months). We concluded that NOEV treatment at the early stage of disease is mandatory for prevention of the brain damage. This result indicated the following sequence of events in the mouse brain. 49 After oral administration, NOEV goes directly into the bloodstream without intestinal digestion, is delivered to the brain through the blood-brain barrier, and restore the mutant β-galactosidase activity, resulting in substrate digestion and clinical improvement. No specifi c adverse effects have been observed for at least 6 months of continuous oral administration. For achievement of clinical drug development, however, we need to study further possible adverse effects and to establish the optinal dose and frequency of administration in order to achieve the best clinical effect.
Molecular Mechanisms of Chaperone Effect in Lysosomal Disease
As described above, β-galactosidase gene mutations result in excessive accumulation of substrates and various clinical phenotypes: G M1 -gangliosidosis and Morquio B disease. Single base substitutions do not necessarily lead to a complete loss of enzyme function. However, the enzyme activity is not always expressed even if the potential catalytic function is not completely lost, simply because of intracellular instability of the mutant enzyme molecule due to inappropriate or incorrect protein folding. Molecular pathology of this type occurs at least in one-third of the patients with β-galactosidase deficiency. 16 Chemical chaperone corrects the molecular abnormality of this type, and assists intracellular transport to the lysosome, fi nally releasing the mutant enzyme as a stable bioactive protein (Fig. 4) .
We postulated that enzyme-chaperone binding would become less strong under the acidic condition in the lysosome. Then the mutant enzyme molecule is released and stable catalytic activity appears. However, the precise mechanism of this NOEV effect is unknown at present. We therefore started computational analysis for prediction of molecular interactions between the β-galactosidase protein and the chaperone compound NOEV.
First, the three-dimensional structure of human enzyme was predicted employing a homology modeling method 3D-JURY, 58, 59 because the structure of this enzyme is not yet available. Penicillium sp. β-galactosidase was used as the template structure for homology modeling, and the predicted structure of human β-galactosidase has been obtained as shown in Figure 5A .
Second, plausible conformation of β-galactosidase-NOEV complex was determined in support of AUTODOCK4. 60 The conformation was subjected to 5A) Sequence identity in the front part was enough to reconstruct its structure and formed a typical TIM barrel domain that is generally found in glycoside hydrolases. In alignment of this part, active residues of both human and Penicillium sp. β-galactosidase molecules were well matched. 5B) Docking of β-galactosidase and NOEV was performed. In the complex of β-galactosidase and NOEV in pH7, the ring part of NOEV was settled in the active pocket. Oxygen of a glutamic acid in β-galactosidase and hydroxyl of amido in NOEV interacted via hydrogen bonding.
further structural optimization. The result of the complex structure was successfully computed by AUTODOCK4 (Fig. 5B) . Third, the binding free energy of the two molecules in the complex was calculated by using AMBER9. 61 The computed binding free energy was −20.08 (kcal/mol) at pH 7.
Fourth, we calculated the effect of low pH in the lysosome on the binding affi nity between the β-galactosidase and NOEV molecules. The low pH effect was represented as protonation of charged residues estimated by PROPKA. 62 The computed binding free energy at pH 5 was −18.06 (kcal/mol); higher than that at pH 7. This result indicates that affi nity between β-galactosidase and NOEV is weakened at pH 5 compared with that at pH 7. Consequently, we concluded that (1) the enzyme-NOEV complex has lower free energy than the unbound enzyme, and (2) protonation of an active site residue causes free energy change consistent with the chemical chaperone hypothesis.
Conclusion
This new therapeutic strategy (chaperone therapy) is in principle applicable to all lysosomal diseases, if a specifi c compound is developed for each enzyme in question. We have already confi rmed the effect in Fabry disease, G M1 -gangliosidosis, and Gaucher disease. Other related diseases also are currently studied by other investigators. 63, 64 Theoretically this principle can be applied to all other lysosomal diseases. Furthermore, there may well be other genetic diseases to be considered, if molecular pathology in somatic cells has been clarifi ed in detail. We hope studies in this direction will disclose a new aspect of molecular therapy for inherited metabolic diseases with central nervous system involvement in the near future.
